tiprankstipranks
Advertisement
Advertisement

TXMD Stock Latest News

TherapeuticsMD Explains Brief Delay In Annual Filing
Company AnnouncementsTherapeuticsMD Explains Brief Delay In Annual Filing
11d ago
TXMD
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
PremiumCompany Announcements
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
13d ago
8K
TXMD
TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year
PremiumThe Fly
TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year
13d ago
TXMD
TherapeuticsMD Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
TherapeuticsMD Approves Key Proposals at Annual Meeting
4M ago
8K
TXMD
TherapeuticsMD Reports Q3 2025 Financial Results
PremiumCompany Announcements
TherapeuticsMD Reports Q3 2025 Financial Results
5M ago
8K
TXMD
TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year
PremiumThe FlyTherapeuticsMD reports Q3 EPS 0c vs. (5c) last year
5M ago
TXMD
TherapeuticsMD Reports Improved Q2 2025 Results
Premium
Company Announcements
TherapeuticsMD Reports Improved Q2 2025 Results
8M ago
TXMD
TherapeuticsMD Reports Q2 2025 Financial Results
Premium
Company Announcements
TherapeuticsMD Reports Q2 2025 Financial Results
8M ago
8K
TXMD
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
PremiumThe Fly
TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year
8M ago
TXMD
TherapeuticsMD Reports Improved Q1 2025 Results
PremiumCompany Announcements
TherapeuticsMD Reports Improved Q1 2025 Results
11M ago
TXMD
TherapeuticsMD Reports Q1 2025 Financial Results
PremiumCompany Announcements
TherapeuticsMD Reports Q1 2025 Financial Results
11M ago
8K
TXMD
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
PremiumThe Fly
TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
11M ago
TXMD
TherapeuticsMD Reports Improved Financial Performance
PremiumCompany AnnouncementsTherapeuticsMD Reports Improved Financial Performance
1y ago
TXMD
TherapeuticsMD Reports Reduced Losses and Revenue Growth
Premium
Company Announcements
TherapeuticsMD Reports Reduced Losses and Revenue Growth
1y ago
8K
TXMD
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
Premium
Company Announcements
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
1y ago
TXMD
TherapeuticsMD Shifts Focus with Lower Q3 Losses
PremiumCompany Announcements
TherapeuticsMD Shifts Focus with Lower Q3 Losses
1y ago
8K
TXMD
TherapeuticsMD Releases Preliminary Quarterly Financial Results
PremiumCompany Announcements
TherapeuticsMD Releases Preliminary Quarterly Financial Results
2y ago
8K
TXMD
TherapeuticsMD Releases Preliminary Q1 2024 Financials
PremiumCompany Announcements
TherapeuticsMD Releases Preliminary Q1 2024 Financials
2y ago
8K
TXMD
TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year
PremiumThe Fly
TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year
2y ago
TXMD
TherapeuticsMD Announces 2023 Annual Financial Results
PremiumCompany AnnouncementsTherapeuticsMD Announces 2023 Annual Financial Results
2y ago
8K
TXMD
60 Degrees Pharmaceuticals appoints Kristen Landon as CCO
Premium
The Fly
60 Degrees Pharmaceuticals appoints Kristen Landon as CCO
2y ago
SXTP
TXMD
Knight Therapeutics announces launch for IMVEXXY in Canada
Premium
The Fly
Knight Therapeutics announces launch for IMVEXXY in Canada
2y ago
TXMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >